Positions

Overview

  • I grew up in Ohio and completed my undergraduate, medical school, and residency training at The Ohio State University. I then went on to complete my fellowship training in gynecologic oncology at UCLA and Cedars-Sinai Medical Center in Los Angeles. I moved to Birmingham to work at UAB because of the amazing multi-disciplinary cancer care team that we have. The UAB health system and Cancer Center are dedicated to being at the cutting edge of providing high quality and well coordinated cancer care.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Evaluating meaningful levels of financial toxicity in gynecologic cancersInternational Journal of Gynecological Cancer.  31:801-806. 2021
    2021 The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?Gynecologic Oncology.  160:800-804. 2021
    2021 Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patientsGynecologic Oncology.  160:793-799. 2021
    2021 Measuring Financial Distress and Quality of Life Over Time in Patients With Gynecologic Cancer-Making the Case to Screen Early in the Treatment Course.JCO Oncol Pract.  OP2000907. 2021
    2020 How, when, and with whom should cost of care conversations occur? preferences of two distinct cancer survivor groups 2020
    2020 Extensive financial hardship among gynecologic cancer patients starting a new line of therapyGynecologic Oncology.  156:271-277. 2020
    2020 Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment modelsGynecologic Oncology2020
    2019 Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgeryInternational Journal of Gynecological Cancer.  29:1156-1163. 2019
    2019 Corrigendum to “Financial toxicity – An overlooked side effect” (Gynecologic Oncology (2018) 150(1) (3–6), (S0090825818308990), (10.1016/j.ygyno.2018.05.012))Gynecologic Oncology.  154:449. 2019
    2019 Perspectives on conversations about costs of cancer care of breast cancer survivors and cancer center staff: A qualitative studyAnnals of Internal Medicine.  170:S54-S61. 2019
    2019 Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancerGynecologic Oncology.  152:445-451. 2019
    2019 Emerging From the Haze: A Pilot Study Evaluating Feasibility of a Psychoeducational Intervention to Improve Cancer-Related Cognitive Impairment in Gynecologic Cancer Survivors.Journal of Palliative Care.  34:32-37. 2019
    2019 Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancerJournal of Surgical Oncology.  120:779-785. 2019
    2018 Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.Gynecologic Oncology.  151:501-505. 2018
    2018 Treatment of low-grade endometrial stromal sarcoma in a nulligravid womanGynecologic Oncology.  151:6-9. 2018
    2018 Financial toxicity – An overlooked side effectGynecologic Oncology.  150:3-6. 2018
    2018 Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare ProvidersJournal of Genetic Counseling.  27:177-186. 2018
    2017 ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian CancerJournal of Oncology Practice.  13:e1030-e1039. 2017
    2015 Robotic Hysterectomy for Endometrial Cancer in Obese Patients With Comorbidities: Evaluating Postoperative ComplicationsInternational Journal of Gynecological Cancer.  25:1271-1276. 2015
    2015 Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.Gynecologic Oncology.  138:689-693. 2015
    2015 Predicting inpatient stay lasting 2 midnights or longer after robotic surgery for endometrial cancer. 2015
    2014 Training the next generation of robotic surgeons using guided mentorship: a randomized controlled trial. 2014
    2013 Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care.Gynecologic Oncology.  131:508-511. 2013
    2011 Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatmentJournal of Controlled Release.  151:239-245. 2011
    2008 Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature.World Journal of Surgical Oncology.  6:117. 2008
    2008 Biphasic anaphylactic reaction to blue dye during sentinel lymph node biopsy.World Journal of Surgical Oncology.  6:79. 2008
    2007 Current immunotherapeutic strategies in breast cancer.Surgical Oncology Clinics of North America.  16:841-ix. 2007

    Research Overview

  • I am interested in studying the out of pocket costs that gynecologic cancer patients face while undergoing diagnosis, treatment, and follow-up. These costs can lead patients to experience financial distress and decrease in quality of life.

    I am working to develop ways to provide:
    - universal screening for financial distress
    - improved communication about the anticipated costs of care
    - resources to identify assistance programs and decrease this financial burden on patients
    - education for patients to help them plan and make informed decisions with their health care providers
  • Investigator On

  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2021 - 2026
  • Private Grant  awarded by Leap Therapeutics, Inc. 2021 - 2026
  • Private Grant  awarded by SEAGEN INC 2021 - 2026
  • UAB 18107 - A Phase 2, Single Arm Study of Atezolizumab + Bevacizumab in Women with Advanced, Recurrent or Persistent Endometrial Cancer  awarded by University of Oklahoma 2020 - 2025
  • Emotional Well-Being and Economic Burden Research Network  awarded by NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH/NIH/DHHS 2021 - 2025
  • The Role of Multilevel Access Dimensions in Ovarian Cancer Disparities  awarded by Duke University 2019 - 2024
  • Private Grant  awarded by TESARO, INC. 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • Private Grant  awarded by CELSION CORPORATION 2018 - 2023
  • Private Grant  awarded by GENMAB 2018 - 2023
  • Private Grant  awarded by AGENUS, INC. 2020 - 2023
  • Private Grant  awarded by Leap Therapeutics, Inc. 2017 - 2022
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2022
  • Comprehensive Cancer Center Core Support Grant - Expanding Distress Screening To Optimize Identification Of Cancer Patients Experiencing Financial Hardship To Enhance Delivery Of Financial Navigation Services  awarded by National Cancer Institute/NIH/DHHS 2019 - 2022
  • Therapeutic Use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial  awarded by Hutchinson (Fred) Cancer Research Center 2020 - 2022
  • Private Grant  awarded by ABBVIE INC 2015 - 2021
  • Private Grant  awarded by TESARO, INC. 2016 - 2021
  • Feasibility & Impact of A Comprehensive Telehealth Program on Reducing Geographic Barriers to Treatment and Improving Symptom Management in Rural Patients with Advanced Ovarian Cancer  awarded by NATIONAL COMPREHENSIVE CANCER NETWORK 2020 - 2021
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2021
  • OB/GYN Faculty Research Career Development Program  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2018 - 2020
  • Private Grant  awarded by TAPIMMUNE, INC. 2018 - 2020
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2018 - 2019
  • Education And Training

  • Doctor of Medicine, Ohio State University System : Columbus 2010
  • The Ohio State University, Residency 2014
  • UCLA, Postdoctoral Fellowship 2017
  • Full Name

  • Margaret Liang